Tenvie
53 employees on LinkedIn · 5 known investors
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases. The company is led by a team with expertise in biotech and precision medicine, targeting treatments for patients and caregivers affected by neurological conditions.
Also known as Tenvie Therapeutics · Tenvie Therapeutics, Inc.
Founders & leadership
Investors · 5
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$200M disclosed across 1 of 2 rounds · 2025
- $200MraisedJan 2025 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Tenvie Therapeutics is a biotechnology company engineering small molecule therapies intended to treat neurological and peripheral diseases, including neurological, cardiometabolic and ophthalmic indications. The company describes a "small molecule product engine" built on a CNS-centric approach that produces both fully CNS-penetrant assets and peripherally restricted assets, giving it optionality across central and peripheral clinical development. Its stated scientific framework rests on three biological pillars: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function, together with translational work on target- and pathway-specific biomarkers to support mechanism of action, indication selection and patient selection.
The disclosed pipeline centers on two lead clinical candidates. TNV262 is a fully CNS-penetrant NLRP3 inhibitor that entered a Phase 1 first-in-human single- and multiple-ascending-dose study in healthy volunteers and persons with obesity, with first subject dosed on April 6, 2026 and preliminary data expected in the second half of 2026. TNV108 is an allosteric SARM1 inhibitor that entered a Phase 1 single- and multiple-ascending-dose study in healthy volunteers, with first subject dosed on April 20, 2026 and preliminary data also expected in the second half of 2026. A third-party profile additionally cites preclinical programs including TRPML1 and TMEM175 agonists. In October 2025 the company posted a bioRxiv preprint describing TN-783, a CNS-penetrant small molecule NLRP3 inhibitor reported to reduce hypothalamic neuroinflammation and microglial activation and to produce durable, fat-preferring weight loss in diet-induced obese mice; the work was highlighted by Alzforum.
Tenvie's stated therapeutic area map spans neurological disease, ophthalmology, metabolic syndrome, cardiometabolic disease, peripheral neurology and peripheral inflammation, on the rationale that these areas share biological drivers such as inflammation, metabolic disruption and lysosomal dysfunction."]
Founding story
According to a third-party profile, Tenvie was founded in 2025 as a spinout from Denali Therapeutics, built around programs acquired from Denali and a team of experienced CNS drug developers. Co-founder Tony Estrada previously served as Senior Vice President and Head of Discovery Sciences at Denali Therapeutics, where he led the therapeutic discovery organization, and oversaw the programs subsequently acquired from Denali by Tenvie. The company's name is presented as a construction of "Ten" (tenacious) and "vie" (lives), referring to a tenacious pursuit to improve the lives of patients and caregivers.
Business model
Tenvie is a preclinical-to-clinical stage biotechnology company that develops wholly owned small molecule drug candidates internally and advances them through IND-enabling work and clinical trials. It is financed by venture capital rather than product revenue, and a third-party profile characterizes its approach as advancing multiple clinical assets without early partnerships; a Chief Business Officer was hired in 2026 to lead strategic collaborations and business operations.
Traction
Two candidates entered Phase 1 first-in-human studies within roughly two weeks of each other in April 2026 (TNV262 and TNV108), with preliminary data guided for the second half of 2026 and first NLRP3 biomarker data indicated for Q4 (per a June 2026 summit summary). Preclinical data on TN-783 were released as a bioRxiv preprint in October 2025 and highlighted by Alzforum. A third-party profile reports 14 employees in South San Francisco and $200 million raised in one round.
Latest developments
The most recent disclosed items are a June 18, 2026 fireside chat at the UBS Private Biotech Innovation Summit, where CEO Tony Estrada discussed the company's CNS-penetrant obesity/cardiovascular thesis and indicated first NLRP3 biomarker data in Q4; the April 2026 initiation of Phase 1 dosing for TNV262 and TNV108; and the February 2026 appointment of Don O'Sullivan as Chief Business Officer.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
A venture-backed, clinical-stage biotech that launched with a $200 million financing, positioned around brain-penetrant small molecules as an alternative or complement to biologic approaches to CNS delivery. A third-party profile describes the company as recycling proven CNS assets from Denali into a focused biotech and competing with larger players in neurodegeneration and metabolic disease.
Stated differentiators include parallel generation of fully CNS-penetrant and peripherally restricted assets from shared chemotypes; wholly owned pipeline assets; a leadership and board team drawn from Denali Therapeutics and Genentech with prior CNS clinical candidate experience; and a three-pillar biology focus (inflammation, metabolic dysfunction, lysosomal function) applied across both central and peripheral indications.
Technology
Tenvie's platform is a small molecule discovery engine focused on optimizing molecular delivery properties. The company states that molecules achieving complete and deep brain penetration occupy a narrow chemical property space, and that it uses foundational CNS chemotypes as starting points and applies disciplined property tuning to generate fully CNS-penetrant leads, then derivatizes those chemotypes to produce peripherally restricted assets. Translational work focuses on targeted and unbiased identification and validation of target- and pathway-specific biomarkers. Disclosed targets include NLRP3 (TNV262, TN-783) and SARM1 (TNV108, an allosteric inhibitor), with a third-party profile citing preclinical TRPML1 and TMEM175 agonist programs.
Go-to-market
The company advances wholly owned candidates through in-house discovery and clinical development, and communicates via press releases, scientific preprints (bioRxiv), coverage in trade press (Endpoints News, Fierce Biotech, STAT, BioCentury, BioWorld), and investor conferences such as the UBS Private Biotech Innovation Summit. A Chief Business Officer with corporate development experience was appointed in February 2026 to lead strategic collaborations.
Patients and caregivers affected by neurological and peripheral diseases, spanning neurological, ophthalmic, metabolic syndrome, cardiometabolic, peripheral neurology and peripheral inflammatory conditions, including obesity.
Geography
Headquartered in the San Francisco Bay Area, California; company press releases are datelined South San Francisco, CA (2025) and Brisbane, CA (2026), and a third-party profile lists the HQ as South San Francisco, CA, USA.
History
Tenvie launched publicly on January 8, 2025, announcing $200 million in financing led by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, with the stated purpose of advancing a pipeline in neurological, cardiometabolic and ophthalmic diseases. On July 23, 2025 the board promoted co-founder Tony Estrada, Ph.D., to President and Chief Executive Officer; the appointment was picked up by Yahoo! Finance, BioCentury, BioWorld, Endpoints News, Fierce Biotech and STAT. In October 2025 the company released a preprint on its CNS-penetrant NLRP3 inhibitor TN-783 in diet-induced obesity, which Alzforum highlighted. Don O'Sullivan, Ph.D., MBA, was appointed Chief Business Officer on February 18, 2026. The first two clinical candidates from the company's product engine entered Phase 1 in April 2026 (TNV262 on April 6 and TNV108 on April 20), and in June 2026 CEO Tony Estrada presented at the UBS Private Biotech Innovation Summit in a fireside chat with Mike Yee.
Risks & controversies
No controversies are reported in the available sources. The sources indicate all disclosed programs are in Phase 1 or preclinical stages with no efficacy data in humans yet, and no revenue or partnership income is described. Source data are inconsistent on some basics: one aggregator lists an employee band of 1001-5000 while its own narrative states 14 employees, and it lists a Series A dated January 1, 2025 versus the January 8, 2025 announcement; a January 2025 press item also lists Tony Estrada's then-title as President and Chief Scientific Officer, which differs from his later CEO title.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlap
Companies competing with Tenvie for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 8
launches, deals, and filingsCEO, President and co-founder Tony Estrada participated in a fireside chat with Mike Yee outlining Tenvie's approach to neurological and peripheral diseases; first NLRP3 biomarker data indicated for Q4 in support of a CNS-penetrant obesity/cardiovascular thesis.
Second candidate from Tenvie's product engine to enter clinical development. The Phase 1 first-in-human study evaluates single and multiple ascending doses of TNV108 in healthy volunteers; preliminary data expected in H2 2026.
First candidate from Tenvie's product engine to enter clinical development. The Phase 1 first-in-human study evaluates single and multiple ascending doses of TNV262 in healthy volunteers and persons with obesity; preliminary data expected in H2 2026.
Tenvie appointed Don O'Sullivan, previously Chief Business Officer at Asher Bio and a 12-year Genentech/Roche executive, as Chief Business Officer to lead strategic collaborations and business operations.
Alzforum featured Tenvie's preprint describing TN-783's reduction of inflammation-driven microglial activation and resulting fat-preferring weight loss in obese mice.
Tenvie posted a bioRxiv preprint reporting that TN-783, an investigational CNS-penetrant small molecule NLRP3 inhibitor, reverses hypothalamic inflammation and achieves durable weight loss in diet-induced obese mice.
Tenvie's board promoted co-founder Tony Estrada to President and CEO to drive the pipeline of CNS-penetrant and peripherally restricted small molecules toward clinical milestones. Coverage appeared in Yahoo! Finance, BioCentury, BioWorld, Endpoints News, Fierce Biotech and STAT.
Tenvie launched publicly with a $200 million investment led by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, to advance a pipeline of small molecule therapeutics for neurological, cardiometabolic and ophthalmic diseases; most advanced programs target NLRP3 and SARM1.
$200M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Tenvietenvie.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Tenvie do?
- Denali spinout developing precision-engineered CNS-penetrant and peripherally restricted small molecules for neurological and peripheral diseases.
- Who are Tenvie's investors?
- Tenvie's investors include ARCH Venture Partners, F-Prime Capital.
- How much funding has Tenvie raised?
- Tenvie has disclosed $200M raised across 1 of its 2 known rounds.